Article Sidebar

Submitted
28 December 2017
Accepted
28 December 2017
Published
28 December 2017
Download
PDF
Statistic
Read Counter : 1084 Download : 940

Main Article Content

Abstract

Methyldopa is the main antihypertensive drug widely used in pregnant women with hypertensive disorder. It lowers blood pressure in pre-eclampsia by affecting a2-adrenoreceptors in central nervous system. However, it also decreases the production of proangio-genic factors that involved in the pathophysiology of hypertension in pre-eclampsia. Vascular Endothelial Growth Factor (VEGF) is one of proangiogenic and mitogenic factor that important for vasodilatation. VEGF is produced by the placenta and affected after treatment with methyldopa. The aim of this study was to analyze the effects of methyldopa on VEGF maternal circulating level as a proangiogenic factor in severe pre-eclampsia patients who were hospitalized at Obstetrics and Gynecology Department, Haji Hospital, Surabaya. This study was performed by cohort prospective observational method on August to October 2016.The data was assessed at before and 48 hours after methyldopa therapy. The study was approved by the ethical committee of Haji Hospital, Surabaya. There were 19 patients with severe pre-eclampsia who met inclusive criteria. The results showed that levels of VEGF before and 48 hours after 250 mg methyldopa therapy were 1178.37(281.97-3567.28) pg/mL and 1055.17 (129.79-4272.66) pg/mL, respectively. VEGF levels in severe pre-eclampsia patients were 1194.29 (175.68-3432.01) pg/mL at before treatment and 510.66 (214.34-1236.16) pg/mL after treatment with methyldopa 500 mg therapy. In conclusion, methyldopa could decrease VEGF level on severe pre-eclampsia patients, with a decrease of 10% at the dose of 250 mg and 57% at the dose of 500 mg.

Keywords

Methyldopa severe pre-eclampsia VEGF

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Juwita, D. R., Yulistiani, Y., & M, E. Z. (2017). EFFECTS OF METHYLDOPA ON VEGF LEVELS AS PROANGIOGENIC FACTOR IN SEVERE PRE-ECLAMPSIA AT HAJI HOSPITAL, SURABAYA. Folia Medica Indonesiana, 53(4), 267–271. https://doi.org/10.20473/fmi.v53i4.7159
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Angsar MD (2010). Hipertensi dalam kehamilan. In S. Prawirohardjo, Ilmu Kebidanan, Jakarta, PT. Bina Pustaka Sarwono Prawirohardjo, p 530-50
  2. Arulkumaran N, Lightstone L (2013). Severe pre-eclampsia and hypertensive crises. Best Practice & Research Clinical Obstetrics and Gynecology 27, 877-84
  3. Bosio PM, Wheeler T, Anthony F, et al (2001). Mater-nal plasma vascular endothelial growth factor concen-trations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. American Journal of Obstetric & Gynecology, 146-52
  4. Cnossen JS, Vollebregt KC, de Vrieze N, et al (2008). Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis'. BMJ 336, 1117
  5. Cunningham F, Leveno KJ, Bloom SL, et al (2010). Williams obstetric. 23th ed, New York, McGraw-Hill Education, p 707-56
  6. Duley L (2009). The global impact of pre-eclampsia and eclampsia. Seminar of Perinatology 33, 130-7
  7. Easterling TR, Benedetti TJ, Schmucker BC, Millard SP (1990). Maternal hemodynamics in normal and pre-eclamptic pregnancies: a longitudinal study. Obstetrics & Gynecology 76, 1061-9
  8. Ferrara N, Davis-Smyth T (1997). The biology of vas-cular endothelial growth factor. Endocrine Reviews 18, 4-25
  9. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Medicine 1, 27-31
  10. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR (2008). Pathophysiology of hypertension during pre-eclampsia: linking placental ischemia with endo-thelial dysfunction. Am.J.Physiol Heart Circ Physiol 294, 541-50
  11. Hasibuan FS, Aminuddin M (2012). Hipertensi pada geriatri. In: Pikir BS, Aminuddin M, Subagjo A, Dhar-madjati BB, et al, Hipertensi manajemen kompre-hensif, Surabaya, Universitas Airlangga
  12. Khalil A, Muttukrishna S, Harrington K, Jauniaux E (2008). Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factor in pregnan-cies with hypertensive disorders. PLoS ONE 3, e2766
  13. Lam C, Lim K, Karumanchi S (2005). Circulating angiogenic factors in the pathogenesis and prediction of pre-eclampsia. Hypertension, 1077-85
  14. Lee ES, Oh MJ, Jung JW (2007). The levels of circu-lating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by pre-eclampsia'. J Korean Me Sci 22, 94-8
  15. Levine RJ, Maynard SE, Qian C, et al (2004). Circu-lating angiogenic factors and the risk of pre-eclamp-sia. The New England Journal of Medicine 304, 672-83
  16. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N (2003). Materal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstetricia et Gynecologica Scandinavica 82, 797-802
  17. McPhee SJ, Ganong WF (2006). Pathophysiology of disease: an introduction to clinical medicine. 5th ed, United States, The McGraw-Hill Companies, Inc, p 295-317
  18. Norwitz E, Hsu C, Repke J (2002). Acute complications of pre-eclampsia. Clinical Obstetric and Gynecology 45, 308-29
  19. RI, Kementrian Kesehatan (2012). Upaya percepatan penurunan angka kematian ibu
  20. Sulistyowati S, Roswendi A, Kartika H, Respati SH (2014). Kadar soluble human leukocyte antigen-G (sHLA-G), vascular endothelial growth factor (VEGF) dan soluble Fms-like tyrosine kinase-1 (sFLT-1) pada pre-eklampsia. Majalah Obstetri & Gynecology 22, 126-31
  21. Zhang ZH, Yin DZ, Wang ZC (2011). Contribution of hypoxia-inducible factor-1alpha to transcriptional re-gulation of vascular endothelial growth factor in bovine developing luteal cells. Animal Science Journal 82, 244-50